RBC Capital Reiterates Outperform on Edgewise Therapeutics, Maintains $32 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Leonid Timashev has reiterated an Outperform rating on Edgewise Therapeutics (NASDAQ:EWTX) and maintained a $32 price target.
July 25, 2024 | 3:46 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital has reiterated an Outperform rating on Edgewise Therapeutics and maintained a $32 price target, indicating continued confidence in the company's performance.
The reiteration of an Outperform rating and the maintenance of a $32 price target by RBC Capital suggests strong confidence in Edgewise Therapeutics' future performance. This positive analyst rating is likely to boost investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100